Crispr Therapeutics reports Q2 EPS ($2.40), consensus ($1.40)

Reports Q2 revenue $892,000, consensus $6.44M. “We are entering the second half of the year with momentum across both our commercial and clinical programs,” said Samarth Kulkarni, chairman and CEO of Crispr Therapeutics (CRSP). “The activation of 75 authorized treatment centers for CASGEVY has been achieved, marking a meaningful step in expanding patient access, while clinical trials across multiple other programs continue to advance. Looking ahead, we expect several key milestones including the presentation of complete Phase 1 data for CTX310, as well as updates across our oncology and autoimmune portfolios. Our focus remains on delivering transformative therapies for patients with critical unmet needs.”